エメンド・バイオセラピューティクス、オムニ・ヌクレアーゼ・プログラムでタケダとの協力におけるマイルストーンを達成
August 20, 2019 09:00 ET
|
Emendo Biotherapeutics
ニューヨーク発 , Aug. 20, 2019 (GLOBE NEWSWIRE) -- エメンド・バイオセラピューティクス (Emendo Biotherapeutics) は本日、武田薬品工業株式会社 (Takeda Pharmaceutical Company Limited、タケダ)...
Emendo Biotherapeutics Achieves Milestone of Collaboration with Takeda for its OMNI Nuclease Program
August 20, 2019 09:00 ET
|
Emendo Biotherapeutics
NEW YORK, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Emendo Biotherapeutics today announced that the company achieved the first milestone as laid out in the agreements with Takeda Pharmaceutical Company...
Emendo Biotherapeutics Enters Into Licensing Option Agreement With Takeda for its OMNI Nuclease Program
April 29, 2019 13:11 ET
|
Emendo Biotherapeutics
NEW YORK, April 29, 2019 (GLOBE NEWSWIRE) -- Emendo Biotherapeutics Inc. today announced that the company signed a licensing option agreement with Takeda Pharmaceutical Company Limited. As part of...